EP
DNTH icon

Elkfork Partners’s Dianthus Therapeutics DNTH Stock Holding History

Elkfork Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$17K Hold
105
– – ﹤0.01% 1037
2019
Q2 		$25K Hold
105
– – ﹤0.01% 1023
2019
Q1 		$28K Hold
105
– – ﹤0.01% 1005
2018
Q4 		$10K Sell
105
-85
-45% -$11.6K ﹤0.01% 1006
2018
Q3 		$37K Hold
190
– – ﹤0.01% 990
2018
Q2 		$41K Buy
+190
New +$42.9K ﹤0.01% 978

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Elkfork Partners's DNTH Position: Q3 2019 in Review

Elkfork Partners held its Dianthus Therapeutics (DNTH) position steady in Q3 2019 at 105 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Elkfork Partners first reported a position in DNTH in Q2 2018 and has held it in 6 quarters since. The position peaked at $41K in Q2 2018. 72 funds tracked by Wall St. Rank hold DNTH as of Q3 2019.

  • Elkfork Partners held 105 shares of Dianthus Therapeutics worth $17K as of Q3 2019.
  • Elkfork Partners left its Dianthus Therapeutics share count unchanged in Q3 2019.
  • Dianthus Therapeutics made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1037 holding.
  • Elkfork Partners first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Elkfork Partners's Dianthus Therapeutics position peaked at $41K in Q2 2018.
  • 72 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.